Joseph T Patterson, Gerard P Slobogean, Joshua L Gary, Renan C Castillo, Reza Firoozabadi, Anthony R Carlini, Manjari Joshi, Lauren E Allen, Yanjie Huang, Michael J Bosse, William T Obremskey, Todd O McKinley, J Spence Reid, Robert V O'Toole, Nathan N O'Hara
OBJECTIVES: To estimate the generalizability of treatment effects observed in the VANCO trial to a broader population of patients with tibial plateau or pilon fractures. METHODS: Design and Setting: Clinical trial data from 36 United States trauma centers and Trauma Quality Programs registry data from more than 875 Level I-III trauma centers in the United States and Canada.Patient Selection Criteria: Patients enrolled in the VANCO trial treated with intrawound vancomycin powder from January 2015 to June 2017 and 31,924 VANCO-eligible TQP patients admitted in 2019 with tibial plateau and pilon fractures...
January 1, 2024: Journal of Orthopaedic Trauma